Evidence map›Paper›PMID 33720773›Full record

ArticleCirculation2021

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.

Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm, Nikolaus Marx

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05754827 (Red Blood Cell Distribution Width to Platelet Count Ratio as a Predictor of Cardiovascular Complications in CKD Patients), which is not on this map. Cited by 1,136 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,136citing papers in PubMed, 10 pooled it
183.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05754827 unknown statusnot on this mapstarted 2023, after this paper: background citation

Red Blood Cell Distribution Width to Platelet Count Ratio as a Predictor of Cardiovascular Complications in CKD Patients

TypeobservationalSponsorSohag UniversityRan2023 to 2024Enrolled100ConditionsCardiovascular ComplicationArmsRDW to platlet count ratio
3 · Its place in the literature

Who cites it

1,136 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,721 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.Journal of the American Society of Nephrology : JASN · 2026
    Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Review

1,076 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Joachim JankowskiInstitute for Molecular Cardiovascular Research (J.J.), University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Aachen, Germany.
Jürgen FloegeDivision of Nephrology and Clinical Immunology (J.F.), University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Aachen, Germany.
Danilo FliserDepartment of Nephrology (D.F.), Saarland University Medical Centre, Homburg, Germany.
Michael BöhmDepartment of Cardiology, Angiology and Intensive Care Medicine (M.B.), Saarland University Medical Centre, Homburg, Germany.
Nikolaus MarxDepartment of Internal Medicine I (Cardiology) (N.M.), University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Aachen, Germany.
Saarland University · DEWestfälische Hochschule · DEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. Although the incidence and prevalence of cardiovascular events is already significantly higher in patients with early CKD stages (CKD stages 1-3) compared with the general population, patients with advanced CKD stages (CKD stages 4-5) exhibit a markedly elevated risk. Cardiovascular rather than end-stage kidney disease (CKD stage 5) is the leading cause of death in this high-risk population. CKD causes a systemic, chronic proinflammatory state contributing to vascular and myocardial remodeling processes resulting in atherosclerotic lesions, vascular calcification, and vascular senescence as well as myocardial fibrosis and calcification of cardiac valves. In this respect, CKD mimics an accelerated aging of the cardiovascular system. This overview article summarizes the current understanding and clinical consequences of cardiovascular disease in CKD.

Indexed as

AdultAgedAged, 80 and overCardiovascular DiseasesFemaleHumansMaleMiddle AgedRenal Insufficiency, ChronicRisk Factorsarrhythmiascardiovascular diseasechronic kidney diseaseclinical aspectsdeathheart failuresudden cardiac

Identifiers

PMID33720773
PMCPMC7969169
OpenAlexW2904356389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.